QNCX
Income statement / Annual
Last year (2023), Quince Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Quince Therapeutics, Inc.'s net income was -$31.39 M.
See Quince Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Cost of Revenue |
$322,000.00 |
$175,000.00 |
$344,000.00 |
$332,000.00 |
$188,000.00 |
$51,000.00 |
$45,000.00 |
Gross Profit |
-$322,000.00 |
-$175,000.00 |
-$344,000.00 |
-$332,000.00 |
-$188,000.00 |
-$51,000.00 |
-$45,000.00 |
Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Research and Development
Expenses |
$9.25 M
|
$25.18 M
|
$60.80 M
|
$61.31 M
|
$30.21 M
|
$10.09 M
|
$9.10 M
|
General & Administrative
Expenses |
$15.40 M
|
$26.01 M
|
$29.52 M
|
$17.59 M
|
$8.95 M
|
$2.03 M
|
$1.27 M
|
Selling & Marketing
Expenses |
-$2.62 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$15.07 M
|
$26.01 M
|
$29.52 M
|
$17.59 M
|
$8.95 M
|
$2.03 M
|
$1.27 M
|
Other Expenses |
$7.48 M |
-$997,000.00 |
-$247,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Operating Expenses |
$24.32 M |
$51.19 M |
$90.32 M |
$78.89 M |
$39.17 M |
$12.12 M |
$10.37 M |
Cost And Expenses |
$24.64 M |
$51.19 M |
$90.32 M |
$78.89 M |
$39.17 M |
$12.12 M |
$10.37 M |
Interest Income |
$3.48 M |
$1.07 M |
$620,000.00 |
$2.04 M |
$2.19 M |
$806,000.00 |
$0.00 |
Interest Expense |
$0.00 |
$568,000.00 |
$0.00 |
$0.00 |
$0.00 |
$957,000.00 |
$1.64 M |
Depreciation &
Amortization |
$322,000.00
|
$175,000.00
|
$344,000.00
|
$332,000.00
|
$188,000.00
|
$51,000.00
|
$45,000.00
|
EBITDA |
-$24.32 M
|
-$50.16 M
|
-$89.97 M
|
-$76.52 M
|
-$36.98 M
|
-$11.26 M
|
-$10.33 M
|
EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Total Other
Income/Expenses Net |
-$6.94 M
|
$71,000.00
|
$373,000.00
|
$2.04 M
|
$2.19 M
|
-$206,000.00
|
-$222,000.00
|
Income Before Tax |
-$31.58 M |
-$51.94 M |
-$89.95 M |
-$76.85 M |
-$36.98 M |
-$12.48 M |
-$12.24 M |
Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Income Tax Expense |
-$197,000.00 |
-$284,000.00 |
-$620,000.00 |
$2.17 M |
-$188,000.00 |
$357,000.00 |
$1.87 M |
Net Income |
-$31.39 M |
-$51.66 M |
-$89.33 M |
-$76.85 M |
-$36.79 M |
-$12.48 M |
-$12.24 M |
Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
EPS |
-0.84 |
-1.54 |
-3.01 |
-2.63 |
-1.93 |
-0.58 |
-0.57 |
EPS Diluted |
-0.84 |
-1.54 |
-3.01 |
-2.63 |
-1.93 |
-0.58 |
-0.57 |
Weighted Average Shares
Out |
$37.24 M
|
$33.50 M
|
$29.72 M
|
$29.18 M
|
$19.03 M
|
$21.55 M
|
$21.55 M
|
Weighted Average Shares
Out Diluted |
$37.24 M
|
$33.50 M
|
$29.72 M
|
$29.18 M
|
$19.03 M
|
$21.55 M
|
$21.55 M
|
Link |
|
|
|
|
|
|
|